A combination of ivermectin 1% cream and oral 40-mg doxycycline has the potential to be an effective therapy for some people with moderate to severe rosacea after the publication of results from a phase 3b/4 study examining the combination’s efficacy and safety compared to ivermectin as a monotherapy.
Susan C. Taylor, M.D., shares distinguishing characteristics of differential diagnoses to keep in mind when examining skin of color patients for rosacea.
It's thought that rosacea affects about 10% of the population, but this estimation may not be completely accurate as the condition is often underdiagnosed – especially in individuals with darker skin types.
Sol-Gel announces updates to their drug pipeline and their goals for 2020, which include submitting multiple provisional patents and NDAs for the treatment of a variety of skin conditions.
Hovione recently published results of a phase 2b study showed a topical gel formulation of 1% and 3% minocycline proved to be an effective and safe treatment for papulopustular rosacea.
Drs. López and Kaufman discuss two new studies that examine the use of ultrasound technology as a new modality for treatment of erythematotelangiectatic and refractory rosacea.
There is still room for improvement to the National Rosacea Society Expert Committee's updated classification schema for rosacea, according to William James, M.D.
A web-based survey indicates erythema severity correlates with rosacea’s quality-of-life impact.
Abnormal proliferation of the Demodex mites is frequent among patients with erythematotelangiectatic rosacea (ETR), according to one expert.
Evidence that points to interleukin-17 playing a role in the development and progression of rosacea also indicates research should investigate IL-17 inhibition as a therapeutic option for some patients, an expert says.